| Tarebiye Pela, MD | |
|
16244 Bennett Rd, Culpeper, VA 22701-4630 | |
| (540) 825-5381 | |
| (540) 829-0945 |
| Full Name | Tarebiye Pela |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 16244 Bennett Rd, Culpeper, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922241801 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 0101262230 (Virginia) | Primary |
| Entity Name | Ut Lebonheur Pediatric Specialists, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093024101 PECOS PAC ID: 7719173939 Enrollment ID: O20101130000117 |
News Archive
People age 65 years and older account for 40 percent of inpatient operations and one-third of outpatient procedures, and these older patients are more vulnerable to longer hospital stays and other complications after surgery than younger patients.
Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
A new study in the British Medical Journal published on December 11, 2019, finds that up to 2 in every 5 prescriptions in the US might not be relevant clinically. This means that clinicians have a long way to go in rational antibiotic use and achieving proper antibiotic stewardship. The characteristics linked with antibiotic prescription without documented indication could help improve practices in this field.
Researchers have finally found the genetic targets that could be used for treatment and development of new drugs in patients who are resistant to chemotherapy. These patients who are resistant to chemotherapy are most likely to have triple negative breast cancer which is the most aggressive form of breast cancer. The study appeared in the latest issue of the journal Cell Metabolism.
› Verified 6 days ago
| Entity Name | Wt Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295223279 PECOS PAC ID: 1951650613 Enrollment ID: O20180814002772 |
News Archive
People age 65 years and older account for 40 percent of inpatient operations and one-third of outpatient procedures, and these older patients are more vulnerable to longer hospital stays and other complications after surgery than younger patients.
Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
A new study in the British Medical Journal published on December 11, 2019, finds that up to 2 in every 5 prescriptions in the US might not be relevant clinically. This means that clinicians have a long way to go in rational antibiotic use and achieving proper antibiotic stewardship. The characteristics linked with antibiotic prescription without documented indication could help improve practices in this field.
Researchers have finally found the genetic targets that could be used for treatment and development of new drugs in patients who are resistant to chemotherapy. These patients who are resistant to chemotherapy are most likely to have triple negative breast cancer which is the most aggressive form of breast cancer. The study appeared in the latest issue of the journal Cell Metabolism.
› Verified 6 days ago
| Entity Name | Wt University Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023572344 PECOS PAC ID: 3779824719 Enrollment ID: O20190401001719 |
News Archive
People age 65 years and older account for 40 percent of inpatient operations and one-third of outpatient procedures, and these older patients are more vulnerable to longer hospital stays and other complications after surgery than younger patients.
Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
A new study in the British Medical Journal published on December 11, 2019, finds that up to 2 in every 5 prescriptions in the US might not be relevant clinically. This means that clinicians have a long way to go in rational antibiotic use and achieving proper antibiotic stewardship. The characteristics linked with antibiotic prescription without documented indication could help improve practices in this field.
Researchers have finally found the genetic targets that could be used for treatment and development of new drugs in patients who are resistant to chemotherapy. These patients who are resistant to chemotherapy are most likely to have triple negative breast cancer which is the most aggressive form of breast cancer. The study appeared in the latest issue of the journal Cell Metabolism.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tarebiye Pela, MD Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Tarebiye Pela, MD 16244 Bennett Rd, Culpeper, VA 22701-4630 Ph: (540) 825-5381 |
News Archive
People age 65 years and older account for 40 percent of inpatient operations and one-third of outpatient procedures, and these older patients are more vulnerable to longer hospital stays and other complications after surgery than younger patients.
Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
A new study in the British Medical Journal published on December 11, 2019, finds that up to 2 in every 5 prescriptions in the US might not be relevant clinically. This means that clinicians have a long way to go in rational antibiotic use and achieving proper antibiotic stewardship. The characteristics linked with antibiotic prescription without documented indication could help improve practices in this field.
Researchers have finally found the genetic targets that could be used for treatment and development of new drugs in patients who are resistant to chemotherapy. These patients who are resistant to chemotherapy are most likely to have triple negative breast cancer which is the most aggressive form of breast cancer. The study appeared in the latest issue of the journal Cell Metabolism.
› Verified 6 days ago
Charles A. Stein, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 15237 Creativity Dr, Culpeper, VA 22701 Phone: 540-321-4281 Fax: 540-321-4282 | |
Mary Alice Shelton Putnam, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 16244 Bennett Rd, Culpeper, VA 22701 Phone: 540-825-5381 Fax: 540-829-0945 | |
Ostranda L. Williams, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 16244 Bennett Rd, Culpeper, VA 22701 Phone: 540-825-5381 Fax: 540-829-0945 | |
Stella A. Debrah-siriboe, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 633 Sunset Ln, Suite A & C, Culpeper, VA 22701 Phone: 540-825-1191 Fax: 540-825-0587 | |
Lisa Harnum, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 15237 Creativity Dr, Culpeper, VA 22701 Phone: 540-321-4281 Fax: 540-321-4282 | |
Susan J. Werner, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 16244 Bennett Rd, Culpeper, VA 22701 Phone: 540-825-5381 Fax: 540-829-0945 | |
Jane Renee Hull, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 16244 Bennett Rd, Culpeper, VA 22701 Phone: 540-825-5381 Fax: 540-829-0945 |